UA92491C2 - Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate - Google Patents

Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate

Info

Publication number
UA92491C2
UA92491C2 UAA200713733A UAA200713733A UA92491C2 UA 92491 C2 UA92491 C2 UA 92491C2 UA A200713733 A UAA200713733 A UA A200713733A UA A200713733 A UAA200713733 A UA A200713733A UA 92491 C2 UA92491 C2 UA 92491C2
Authority
UA
Ukraine
Prior art keywords
tetrahydrofolate
methyl
defects
estrogens
pharmaceutical composition
Prior art date
Application number
UAA200713733A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Кай Штротманн
Кевин Уэлч Смит
Клаус Питрцик
Кристина Кинг
Рудольф Мозер
Original Assignee
Байер Шеринг Фарма Акциенгезельшафт
Мерк Эпрова Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Шеринг Фарма Акциенгезельшафт, Мерк Эпрова Аг filed Critical Байер Шеринг Фарма Акциенгезельшафт
Publication of UA92491C2 publication Critical patent/UA92491C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a pharmaceutical composition which contains gestagens, preferably drospirenone, estrogens, preferably ethinylestradiol, and 5-methyl-(6S)-tetrahydrofolate, can be used as an oral contraceptive, and prevents diseases of the consumer caused by folate deficiency, especially cardiovascular diseases, as well as congenital defects caused by folate deficiency after conceiving the embryo, such as neural tube defects, defects of the ventricular valve, urogenital defects, and cheilognathopalatoschisis, without masking the symptoms of vitamin Bdeficiency while facilitating unrestricted usability of the folate component 5-methyl-(6S)-tetrahydrofolate by the organism and thus the biological activity thereof in order to prevent said congenital defects caused by folate deficiency in case of a homozygous or heterozygous methylenetetrahydrofolate reductase polymorphism. In addition, an extended protective effect is maintained after discontinuing the contraceptive.
UAA200713733A 2005-05-13 2006-05-15 Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate UA92491C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (en) 2005-05-13 2005-05-13 Pharmaceutical composition containing progestogens and / or estrogens and 5-methyl- (6S) -tetrahydrofolate

Publications (1)

Publication Number Publication Date
UA92491C2 true UA92491C2 (en) 2010-11-10

Family

ID=37295493

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200713733A UA92491C2 (en) 2005-05-13 2006-05-15 Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate

Country Status (3)

Country Link
DE (1) DE102005023301B4 (en)
JO (2) JO2561B1 (en)
UA (1) UA92491C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117823B2 (en) 2013-03-12 2018-11-06 Primal Therapies, Inc. Dental composition comprising chelator and base

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693255A5 (en) * 1997-06-13 2003-05-15 Eprova Ag Use of tetrahydrofolates natürlichenstereoisomeren in the form suitable for the preparation of a pharmaceutical composition for influencing the homocysteine ​​level.
DE10022510A1 (en) * 2000-05-10 2001-11-15 Basf Ag Composition used as folate source in food, feed, nutritional supplements or medicaments, e.g. for prophylaxis of cardiovascular disease includes folic acid and 5-methyl-tetrahydrofolic acid
DE60215224T2 (en) * 2002-02-21 2007-08-23 Schering Aktiengesellschaft PHARMACEUTICAL COMPOSITION, CONTAINING ONE OR MORE STEROIDS, ONE OR MORE TETRAHYDROFOLATE COMPOUNDS AND VITAMIN B12

Also Published As

Publication number Publication date
JOP20100287B1 (en) 2022-03-14
DE102005023301B4 (en) 2012-05-31
DE102005023301A1 (en) 2006-11-16
JO2561B1 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
SG169973A1 (en) Pharmaceutical composition containing gestagens and/or estrogens and 5- methyl-(6s)-tetrahydrofolate
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
MX2007005527A (en) Lactam compounds and their use as pharmaceuticals.
WO2007002667A3 (en) Azaindazole compounds and methods of use
WO2006012226A3 (en) N-substituted piperidines and their use as pharmaceuticals
MX340538B (en) Amido compounds and their use as pharmaceuticals.
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
WO2006020598A3 (en) Amido compounds and their use as pharmaceuticals
SV2009003288A (en) DERIVATIVES OF 2, 3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE SUBSTITUTED FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
PH12012501774A1 (en) Pharmaceutical composition containing a tetrahydrofolic acid
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
WO2007146349A3 (en) Cgrp receptor antagonists
CY1111762T1 (en) OUTDOOR OUTDOOR OLANZAPIN
UA92491C2 (en) Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
UA89043C2 (en) Amido compounds and their use as pharmaceuticals
TH105386B (en) Pharmaceutical constituents consisting of progestogens and / or estrogens and 5-methyl- (6S) -tetrahydrofolate.
CU20070252A7 (en) PHARMACEUTICAL COMPOSITION CONTAINING DROSPIRENONE, ETHYLESTRADIOL AND CALCIUM SALT OF 5-METHYL ACID- (6S) -TETRAHYDROPHOLIC
UA94028C2 (en) Amido compounds and their use as pharmaceuticals
TH105386A (en) Pharmaceutical constituents consisting of progestogens and / or estrogens and 5-methyl - (6S) -tetrahydrofolate.
CL2008001974A1 (en) Compounds derived from cyclopenta [d] pyrimidine inhibitors of the kinase akt; Preparation process; pharmaceutical kit; pharmaceutical composition and use in the treatment of inflammatory, hyperproliferative, cardiovascular, neurodegenerative diseases, among others.
TW200630087A (en) Medicinal composition comprising with lowering blood free fatty acid